These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25637377)

  • 1. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ
    Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Jameson M; Deckersbach T; Loh R; Thompson-Hollands J; Jenike M; Keuthen NJ
    Int Clin Psychopharmacol; 2009 Nov; 24(6):306-11. PubMed ID: 19730388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
    McDougle CJ; Barr LC; Goodman WK; Pelton GH; Aronson SC; Anand A; Price LH
    Am J Psychiatry; 1995 Dec; 152(12):1812-4. PubMed ID: 8526253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.
    Dell'osso B; Mundo E; Marazziti D; Altamura AC
    J Psychopharmacol; 2008 Mar; 22(2):210-3. PubMed ID: 18208931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder.
    Costa DLDC; Barbosa VS; Requena G; Shavitt RG; Pereira CAB; Diniz JB
    J Psychopharmacol; 2017 Oct; 31(10):1312-1322. PubMed ID: 28441896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
    Feusner JD; Kerwin L; Saxena S; Bystritsky A
    Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias.
    Stein DJ; Hollander E; Anthony DT; Schneier FR; Fallon BA; Liebowitz MR; Klein DF
    J Clin Psychiatry; 1992 Aug; 53(8):267-71. PubMed ID: 1386848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obsessive-compulsive hoarding: symptom severity and response to multimodal treatment.
    Saxena S; Maidment KM; Vapnik T; Golden G; Rishwain T; Rosen RM; Tarlow G; Bystritsky A
    J Clin Psychiatry; 2002 Jan; 63(1):21-7. PubMed ID: 11838621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence.
    Bent AE; Gousse AE; Hendrix SL; Klutke CG; Monga AK; Yuen CK; Muram D; Yalcin I; Bump RC
    Neurourol Urodyn; 2008; 27(3):212-21. PubMed ID: 17580357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of psychotropic agents for the symptoms of obsessive-compulsive disorder.
    Brakoulias V; Starcevic V; Berle D; Milicevic D; Moses K; Hannan A; Sammut P; Martin A
    Australas Psychiatry; 2013 Apr; 21(2):117-21. PubMed ID: 23426097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvoxamine treatment of obsessive-compulsive disorder.
    Perse TL; Greist JH; Jefferson JW; Rosenfeld R; Dar R
    Am J Psychiatry; 1987 Dec; 144(12):1543-8. PubMed ID: 3120604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions.
    Rosario-Campos MC; Miguel EC; Quatrano S; Chacon P; Ferrao Y; Findley D; Katsovich L; Scahill L; King RA; Woody SR; Tolin D; Hollander E; Kano Y; Leckman JF
    Mol Psychiatry; 2006 May; 11(5):495-504. PubMed ID: 16432526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical correlates of social adjustment in patients with obsessive-compulsive disorder.
    Rosa AC; Diniz JB; Fossaluza V; Torres AR; Fontenelle LF; De Mathis AS; da Conceição Rosário M; Miguel EC; Shavitt RG
    J Psychiatr Res; 2012 Oct; 46(10):1286-92. PubMed ID: 22800713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Yale-Brown Scale: instrument for assessing the severity of obsessive-compulsive disorders].
    Kiejna A; Grzesiak M; Małyszczak K
    Psychiatr Pol; 1998; 32(1):69-76. PubMed ID: 9594585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.